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Abstract
Cancer-induced cachexia (CC), characterized by systemic inflammation, body
weight loss, adipose tissue (AT) remodeling, and muscle wasting, is a malignant
metabolic syndrome with an undefined etiology. There is a consensus that multiple
factors contribute to cancer-induced AT remodeling, and longitudinal studies show
that patients lose AT before they start losing muscle mass. In CC, AT remodeling
occurs predominantly through adipocyte atrophy, impairment of fatty acid turn-
over, inflammation, rearrangement of extracellular matrix (ECM), and browning of
AT. More recently, some studies have shown that AT is affected early in the course
of cachexia. Additionally, studies using experimental models have consistently
indicated that the alterations in adipocyte metabolism begin quite early, followed by
the downregulation of adipogenic and thermogenic genes. These sets of changes, in
addition to metabolites derived from this process, maybe the initial (sterile) trigger
of the sequence of events that result in the remodeling and dysfunction of AT in
cachexia. Therefore, the present chapter aims to describe state of the art related to
the subject of interest by analyzing the primary studies that have addressed the
possible interface between inflammation and morphofunctional alterations of
AT, in addition to the possible repercussions of this process during the
development of CC.
Keywords: adipose tissue, cachexia, inflammation, metabolism, adipogenesis,
ECM, browning
1. Introduction
1.1 Etiology of cachexia syndrome and adipose tissue remodeling
Cachexia is a common occurrence in the advanced stages of cancer and contrib-
utes to reduce the quality of life and life expectancy of patients [1, 2]. Cancer-
related cachexia (CC) is a significant cause of morbidity and mortality, affecting
more than 80% of individuals with advanced cancer and accounting for more than
20% of deaths [3–5]. Notably, the severity of cachexia does not correlate with tumor
size [6]. Although there are descriptions of cachectic individuals dating back to
more than 2000 years ago, increased attention has been focused on this syndrome
in the recent decades. Nevertheless, its etiology remains unknown, and there is no
treatment that is able to revert this condition [7, 8].
Cachexia is understood as a complex metabolic syndrome associated with
underlying diseases and is characterized by a reduction of muscle mass and
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a depletion of fat stores [9–11]. Thus, the main clinical symptoms of CC are body
weight loss in adults (corrected for water retention) and impaired (substandard)
growth in children (after exclusion of endocrine disorders) [12]. Anorexia, inflam-
mation, insulin resistance, and increased degradation of muscle proteins are fre-
quently associated with cachexia [1, 2]. Although anorexia exhibits different
characteristics when compared with starvation, muscle mass loss due to aging
(sarcopenia), primary depression, malnutrition, and hyperthyroidism is
correlated with increased morbidity associated with asthenia and metabolic
disorders [3, 13].
Weight loss is the foremost independent predictor of mortality in cancer
patients [8, 12, 14], beginning with the loss of both a fat mass (adipose tissue—AT)
and the lean body mass (skeletal muscle tissue). Over the last few years, the former
has often been proposed to proceed more rapidly in the patient than the latter
[11, 15, 16]. By the late 1980s and early 1990s, cachexia was being approached from
a different perspective, leading to a new conception according to which it is con-
sidered a chronic inflammatory syndrome. It is currently believed that factors
produced by both the tumor and the host cause anorexia and the metabolic abnor-
malities that result in cachexia [3, 17, 18]. Based on the knowledge obtained
regarding cachexia and its complexity, the latest international consensus defined
standard diagnostic criteria for the disease [1]. According to this consensus, the
condition is categorized as pre-cachexia (early stage), cachexia, or refractory
cachexia (late stage) based on the severity of the following parameters: (1) the
reduction of total body mass; (2) the presence of metabolic disorders; (3) anorexia;
and (4) systemic inflammation, as illustrated in Figure 1A.
Figure 1.
Model of cachexia development from a translational point of view. (A) Morphofunctional changes in adipose
tissue described in cancer cachexia patients. These alterations are associated with the stages of syndrome
development, according to [1]. (B) Compilation of main metabolic and inflammatory changes described in the
experimental model of cachexia induced by Walker 256 tumor.
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An accurate understanding of the fundamental mechanisms that underlie CC is
essential for the development of new pharmacological and nutritional therapies. In
this way, several studies [19–23] have suggested that AT is the target of local and
systemic factors derived from the host and by the tumor, including pro-cachectic
factors [tumor necrosis factor α (TNF-α); interleukin (IL) 6; IL-1ß; IL-8; inter-
feron-γ (INF-γ); ciliary neurotrophic factor; and leukemia inhibitory factor], anti-
cachectic factors [soluble TNF-α receptor (sTNFR); soluble IL-6 receptor (sIL-6R);
IL-1 receptor antagonist (IL-1RA); IL-4; IL-10; and IL-15], and tumor products
[proteolysis-inducing factor (PIF); lipid-mobilizing factor (LMF); zinc-α 2-glyco-
protein (ZAG); toxohormone-L; and anemia-inducing substance (AIS)]. Such fac-
tors are involved in the etiology and progression of cachexia [8, 14, 24–29]. Upon
positing the inflammatory model as the hypothesis to be tested, some studies have
recently demonstrated the relevance of subcutaneous adipose tissue (scAT) as both
an important source of inflammatory mediators (particularly IL-6 and adiponectin)
and an important source of biomarkers for cachexia (clinical progression), as
adiponectin expression exhibits a correlation with the magnitude of the total body
mass reduction [20]. More recently, a consistent modification consisting of inflam-
matory cell presence and fibrosis in scAT induced by cachexia was demonstrated in
gastrointestinal cancer patients [30, 31]. The fibrosis was characterized by the
presence of “crown-like structures” composed of CD68 positive AT macrophages
(ATMϕs) surrounding adipocytes, and increased CD3 Ly, both of which were more
evident in the fibrotic areas. In addition, some of these changes were already
present in the cancer group, suggesting that AT inflammation may occur at an early
stage of cachexia, even before the detection of pre-cachexic clinical features. Thus,
alterations in AT inflammation seem to play a crucial role in the changes resulting in
fat mass reduction, in addition to other morphofunctional alterations related to this
tissue [19, 21]. Moreover, these changes appear to start quite early, long before any
local tissue and/or systemic (circulatory system) changes can be detected.
Nevertheless, most studies on this topic have been restricted to assessing
inflammation from the systemic point of view, only investigating plasma parame-
ters, while neglecting tissue inflammation and, particularly, the events that precede
the appearance of these alterations, although they may significantly contribute to
disorders that result in AT remodeling, such as impairment of lipid metabolism,
tissue cells turnover and inflammation, fibrosis, and subsequent systemic inflam-
mation [2, 28]. Additionally, considering the important relationship among infil-
trating cells (inflammatory mediators), the regulation of adipocyte metabolism, and
the consequent remodeling of the AT, few or no studies have investigated this
relationship and its role in the various stages of cachexia to our knowledge.
1.2 General features of adipose tissue remodeling
In general, AT remodeling in CC comprises a set of morphostructural modifica-
tions characterized by adipocyte atrophy, a result of an unbalance of lipids turnover,
main due to increased lipolysis [10, 32]; impairment of adipocyte cellular turnover
(adipogenesis) [18, 19]; enhanced inflammatory signaling [21, 30, 32]; modification
of extracellular matrix (ECM) component generally resulting in fibrosis [30, 31]; and
browning phenotype related to increase thermogenic effect [16, 33–35].
1.2.1 Adipose tissue atrophy is involved in the etiology of cachexia
The basic structure of the various types of AT includes mature adipocytes,
stromal vascular cells (mesenchymal precursor cells, preadipocytes, fibroblasts, and
immune system cells), blood vessels, lymph nodes, and nerves [36]. Fat cells
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(adipocytes) are the main cell type in AT, while the presence of other cell types
varies as a function of the tissue location [mesenteric (meAT), epididymal (epiAT),
retroperitoneal (rpAT), or scAT], animal species, and disease (e.g., obesity and
cachexia) [37]. Additionally, the importance of AT in the control of adiposity is well
established, as is the role of the adipokines (leptin, adiponectin, and resistin, among
others) released by the adipose tissue [38]. While alterations in the development
and metabolism of adipocytes have been implicated in the pathogenesis of human
immunodeficiency virus (HIV)-related lipodystrophy [39], very little is known
about the molecular mechanisms involved in the occurrence of lipodystrophy asso-
ciated with other conditions, such as cachexia.
As mentioned above, in the course of cachexia, the observed body weight loss
predominantly results from a reduction in the fat (AT) and lean (skeletal muscle)
mass [10, 40]. More recently, AT loss was found to precede the reduction of the
lean body mass [11, 15], and thus, a more accurate understanding of this process
began to emerge. Several factors have been suggested as the cause of the changes
that lead to a reduction of AT mass, including (1)increased lipid mobilization due
to increased lipolysis in adipocytes [9, 10]; (2) reduced lipogenesis, resulting
from decreased lipoprotein lipase (LPL) activity [17]; and (3) impaired adipocyte
turnover, most likely as a function of an adipogenesis-apoptosis imbalance
in AT [41].
Taking the factors that are most likely to be involved in the observed fat mass
loss and the relevance of AT in cachexia into consideration, the recent studies have
utilized an experimental animal model that allows temporal assessment of the main
variables that are potentially involved in cachexia-induced AT disorders, with an
emphasis on the parameters related to adipogenesis, metabolism, and inflammation
[18, 23, 27, 32], as shown in Figure 1A. These data demonstrate that these alter-
ations start early, at 4 days after cachexia induction by inoculation of Walker 256
tumor cells in Wistar rats [19, 32]. It is worth noting that this is the period that
precedes the appearance of the classic symptoms of cachexia, such as dyslipidemia,
and a reduction of the total body weight, as well as inflammatory alterations in the
AT in these animals, which begin to predominate starting on Day 7. In Lewis lung
carcinoma (LLC) tumor-bearing mice, upregulation of genes related to lipid turn-
over and adipose browning is evident even before the detection of the body weight
loss of the animals [16, 33]. Similarly, using several experimental models of
cachexia (syngeneic and genetic), K5-SOS mice showed reduction in fat mass and
spleen enlargement in the pre-cachexic period, that is, before the detection of body
weight loss and the development of cachexia [33]. Taking the aforementioned
findings into consideration, the temporal characterization of some of the alterations
that occur in different AT depots in the course of cachexia has effectively pointed to
actual pathways and mediators that might be involved in the earliest changes, in
addition to serving as biomarkers for the clinical progression of cachexia.
As mentioned above, accentuated reduction of fat mass is a significant clinical
sign of CC. Although it has not yet been well established, these alterations depend
on the location of the adipose tissue involved (e.g., visceral or subcutaneous).
Taking this into account, it was recently shown that, considering results found in
the experimental animal model of cachexia (Walker 256 tumors cells-induced),
visceral fat depots were affected in different ways. Thus, epiAT and meAT [25]
exhibited higher reductions in relative weight (percentage of total body mass),
respectively, while rpAT did not show any change [42]. Furthermore, in cachectic
patients, assessment of the adipose tissue area by means of computed tomography
in humans showed that visceral AT was reduced in cachectic individuals with
gastrointestinal carcinosarcoma when compared with controls [43]. On the other
hand, in individuals with gastrointestinal cancer, scAT seems to be more affected
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when compared with visceral AT (epiAT and meAT), at least considering tissue
inflammation parameters [44].
In fact, as described above, AT atrophy is a well-characterized clinical variable
in cachexia syndrome. In addition, this tissue is affected early before the appearance
of classic signs of cachexia. In this sense, the main morphological alteration
observed as a result of AT atrophy is the alterations in the area and perimeter of
adipocytes in both animal models [18, 42] and CC patients [20, 30]. Still in this
context, depot-specific changes in adipocyte ultrastructure [42] were also
described.
1.2.2 Metabolic features of adipocytes in the course of cachexia
The body weight loss in CC has been thought to be a result of profound changes
in metabolic pathways of tissues and organs, which cannot be solely explained by
enhanced energy expenditure or malnutrition [45]. In this regard, the role of early
AT dysfunction seems to have gained importance in the onset and progression of
many alterations induced by the syndrome. Different mechanistic possibilities have
been proposed to explain the changes in AT in cachexia, such as increased lipolytic
activity, decreased the activity of LPL, reduced de novo lipogenesis, and, conse-
quently, decreased lipid triacylglycerol (TG) deposition [32, 45–47]. Adipocyte lipid
turnover [i.e., the balance between incorporation and removal of TG into adipo-
cytes, in which lipolysis (hydrolysis of intracellular TGs)] and is the most important
factor for lipid removal [48]. In CC, human and animal models [11] have shown an
increased rate of lipid mobilization, and longitudinal studies have shown that
patients with CC lose AT mass before wasting of the muscle mass can be detected
[15]. In addition, an accelerated rate of AT loss is believed to be associated with
shorter survival time during cancer progression [49].
Most of the volume (>90%) of a white adipocyte is represented by a single fat
droplet, which is mainly composed of TG. During periods of stress and/or nutrient
deprivation, such as in metabolic disorders, the adipocytes activate mechanisms
that lead to lipolysis, with a consequent release of non-esterified fatty acids
(NEFAs) and glycerol originating in the TG stored in these cells. NEFAs are imme-
diately released into the bloodstream and subsequently serve as a substrate for
energy production of muscle tissues, or alternatively, they are taken up into the
liver, where they are oxidized, esterified, or transformed into ketone bodies [50].
The reactions that result in NEFA release are mainly catalyzed by two enzymes:
adipocyte triglyceride lipase (ATGL), which catalyzes the first step of the pathway,
resulting in the formation of diacylglycerol, and hormone-sensitive lipase (HSL),
which is responsible for additional hydrolysis and catalyzes the reactions that cul-
minate in NEFA and glycerol release [10].
Among the mechanisms that may be involved in the metabolic disorders that
cause fat mass reduction in cachexia, increased lipolysis appears to be the most
evident and is being described as an increasing frequency [9, 11]. Das and col-
leagues found that in ATGL and HSL knockout mice, there was a greater resistance
to the development of tumor-induced cachexia, which was more evident in ATGL-
deficient animals. These authors also observed a positive correlation between ATGL
activity and the severity of cachexia. Even more interestingly, they only detected a
reduction of lean body mass in animals that exhibited severe cachexia. This
phenomenon followed the events that led to a reduction of fat body mass, most
noticeably involving an increase of TG hydrolysis in AT. The results of this study
corroborate findings previously reported in individuals with cancer-related
cachexia [15], thus increasing the consistency of the evidence demonstrating the
role of AT as a target tissue in cachexia. Nevertheless, neither the exact time when
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these changes occur in the course of cachexia nor the various affected depots have
yet been adequately described.
To elucidate these aspects, a study was conducted in which the lipolytic capacity
of isolated adipocytes was assessed at 4 and 14 days after the inoculation of tumor
cells. Two particular visceral fat stores were selected (meAT and rpAT) based on
the results of previous studies that demonstrated their relevance for the develop-
ment of cachexia. Day 4 was selected to perform the analysis, also based on previous
results [19], which demonstrated downregulation of the genes involved in adipo-
cyte metabolism, while no changes were found in the assessed morphological and
inflammatory parameters. Interestingly, the tumor-bearing animals exhibited a
reduction in basal lipolysis 4 days after inoculation, while on Day 14, the cachectic
animals exhibited a considerable increase in the basal lipolysis rate (Figure 1B).
These findings corroborate with the results of other studies showing increased
lipolysis in the subcutaneous AT of cachectic patients [9, 51].
In this regard, another important aspect was a deregulation of lipolysis (in vitro)
revealed a distinct profile, depending on the degree of disease progression. In the
first, the basal rate of lipolysis was reduced and was accompanied by increased
p-HSL (Ser565) expression, which is regulated by AMPK activation and, conse-
quently, inhibits HSL activity. Patients with CC show reduced spontaneous basal
lipolysis with elevated ex vivo responses to catecholamine and natriuretic peptides
[40, 52]. In this aspect, an elegant study showed that the lack of AMPK activity is a
common feature of adipose tissue dysfunction in cachectic mice and is triggered, at
least partially, through the aberrant induction of Cidea and the subsequent degra-
dation of AMPK in this tissue [53]. The authors suggest that treatment of cachectic
animals with a peptide specifically targeting the white adipose tissue AMPK-CIDEA
interaction prevents AT loss under CC conditions.
1.2.3 Downregulation of adipogenic genes in cancer cachexia
Adipogenesis may be defined as the process of the differentiation of precursor
cells (preadipocytes) into new adipose cells (adipocytes) that are able to store TG
and synthesize and secrete various proteins called adipokines [54]. In fact, impaired
adipogenesis might contribute to the development of obesity-related metabolic
disorders, such as peripheral insulin resistance, hyperlipidemia, and type 2 diabetes
[55, 56]. The process of adipocyte differentiation involves the activation of a cas-
cade of transcription factors that coordinate the expression of genes that are
responsible for adipocyte function [55, 57]. The initial events include transient
increases in CCAAT/enhancer-binding proteins beta and delta (C/EBPβ and δ),
which allow preadipocytes to be distinguished from non-adipogenic precursor cells
and subsequently activate the expression of the peroxisome proliferator-activated
receptor gamma-2 (Pparγ-2), which in turn stimulates the expression of C/ebpα,
which exerts a synergic effect with PPARγ-2 on the control of terminal differentia-
tion [54, 57]. Local and endocrine factors might regulate adipogenesis through the
modulation of these transcriptional events [58].
Adipocyte maturation is accompanied by intracellular lipid accumulation, which
is mainly mediated by sterol regulatory element-binding protein-1C (SREBP-1C). In
addition to activating the expression of Pparγ-2, SREBP-1C also activates the
lipogenic pathway by stimulating the expression of the genes that encode the main
enzymes of that pathway, such as ATP-citrate lyase (Acly), acetyl-CoA carboxylase
(Acaca), fatty acid synthase (Fasn), and stearoyl-CoA desaturase-1 (Scd-1) [18, 57].
In addition to its direct participation in adipocyte differentiation, PPARγ-2 also
plays an important role in the transcriptional regulation of genes associated with the
lipogenic pathway by inducing the transcription of genes that encode adipocyte
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fatty acid-binding protein (aP2), LPL, fatty acid transport proteins (FATPs), and
fatty acid-binding proteins (FABPs), among others. Activation of genes associated
with glucose transport, such as Glut4, and thermogenesis, such as the mitochondrial
uncoupling proteins (Ucp2 and Ucp3), has also been described [18].
In AT, a balance between the growth/differentiation (adipogenesis) and
death of its cells (generally by apoptosis) regulates the cellular turnover [41, 59].
In this aspect, the impairment of adipogenesis in the course of cachexia has
been recently addressed. Some studies have elucidated the adipogenic marker
profile during the development of cachexia syndrome [19, 25]. However, few stud-
ies have addressed the apoptotic processes and/or AT turnover during cachexia
[43]. It has been known that adipogenic genes are downregulated in CC in epiAT
[18] and rpAT [19]. On the other hand, scAT apoptosis did not change in cancer
patients [43]. Therefore, considering that AT depots respond heterogeneously to
CC and several metabolic and inflammatory pathways are involved in AT
remodeling, there is no consensus if such effects induced by cachexia would be a
result of secreted products directly by the tumor and tumor-host relationship. Thus,
a recent study has analyzed in vitro adipogenesis in a co-culture system to mimic
the effects of CC on adipocytes [60]. Co-culture of LLC cells promoted a decreased
volume of the lipid droplets in 3 T3-L1 cells, compromising its maturation process
(adipogenesis) in vitro. This result was followed by the downregulation of
adipogenic and lipolytic gene expression, increased in apoptosis markers and
proinflammatory cytokines secretion by both tumor cells and adipocytes. In this
sense, these data suggest that the presence of the tumor cells was able to inhibit
the adipocytes’ maturation, which was associated with the increased levels of
inflammatory cytokines.
In this way, the findings generated in the experimental model have demon-
strated to be adequate for investigating cachexia-induced alterations of
adipogenesis and point to the need to widen the scope of the assessed genes as well
as the pathways and regulatory factors involved. Besides, modifications in
adipogenesis appear to precede the appearance of the classic signs of cachexia as
well as the signs of tissue inflammation in AT, such as increases in infiltrated
macrophages and the production of inflammatory cytokines [21]. Thus, the factors
that “silence” the genes involved in the differentiation of preadipocytes, and, con-
sequently, in the maintenance of adipose cells turnover in AT might play a central
role in the genesis of the damaging changes (metabolism and function) that occur in
the adipose tissue of individuals with cachexia.
1.2.4 Adipose tissue inflammatory profile in the course of cachexia
According to the abovementioned findings from animal models and cancer
cachexia patients, a metabolic and morphological dysfunction that results in the AT
remodeling occurs during the development of CC [2]. More recently, another rele-
vant aspect of cachexia-induced AT remodeling is the establishment of AT inflam-
mation, which is characterized by increased recruitment of ATMϕs, including
activated M1 (pro-inflammatory) and M2 (anti-inflammatory) macrophages [32].
In this way, an inflammatory profile predominates the end-stage of cachexia, par-
ticularly in visceral AT, as most of the characteristic changes of this syndrome are
already established at this time [19, 27]. More recently, the immune cell infiltration
profile was analyzed in greater detail, which was found to be characterized by an
increase in M1-polarized macrophages [20]. In that study, the profile of chemokines
specific to polymorphonuclear cells was also investigated, in addition to the pres-
ence of neutrophils in the various AT depots. The results revealed an increase in the
chemokines CCL3 and CXCL2 at 7 days after tumor cell inoculation. The presence
7
Adipose Tissue Remodeling during Cancer Cachexia
DOI: http://dx.doi.org/10.5772/intechopen.79979
of CD11b-positive cells, which were tested to detect the presence of neutrophils,
was observed in the same period. Taking the temporal changes identified in the
cachexia model into consideration, as a function of the assessed parameters, the
results indicate that inflammation starts on Day 7 and is established by Day 14, a
period during which a series of disorders characteristic of cachexia become evident
(e.g., a reduction of the total body and fat mass, dyslipidemia, and hypoglycemia).
In this regard, even more recently, these findings were presented in greater detail in
cachexia induced by LLC cells, showing ATMϕs polarization tends to be directed to
M1 phenotype [61, 62].
Despite the increasing perception of the importance of the relationship between
inflammation and CC, and systemic inflammation in particular, there is still no
consensus regarding its source and also the role of inflammation of TA in the
establishment and development of cachexia, among cancer patients in particular
[9, 43]. Limitations in experimental designs, the selection of control groups, and the
techniques used to analyze markers of inflammation have most likely been respon-
sible for preventing a more precise investigation of the presence of inflammation in
AT. Addressing this question, a study has recently demonstrated increased gene
expression of phenotypic markers of ATMϕs and inflammatory cytokines, such as
IL-6 and TNF-α, in cachectic patients with gastrointestinal cancer [20]. Interest-
ingly, increased gene levels of IL-6 were positively correlated to increase plasmatic
levels of this cytokine, indicating that in cachectic patients, scAT may be an impor-
tant source of inflammatory mediators. Even more recently, the same group
revealed an increase in ATMϕs forming crown-like structures in the same AT depot
from cachectic patients [44], which is a characteristic finding in fat tissue in exper-
imental animal models of obesity and in obese patients [63]. In addition, an increase
in chemoattractant for ATMϕs gene expression in scAT, such as Ccl2, was detected
only in cancer patients without cachexia, showing no changes in cachectic ones.
However, despite the relevance of local inflammation, in AT in particular, the
mechanisms responsible for both cachexia and inflammation remain to be eluci-
dated. The characterization and understanding of the process of inflammation in
cachexia are also relevant to establish whether it is secondary to or the “trigger” for
the development of cachexia syndrome.
1.2.5 Alterations in the extracellular matrix of adipose tissue
Extracellular matrix (ECM) remodeling is the result of the processes of matrix
synthesis and degradation during which specific proteins are deposited, such as
tenascin and fibrin, and occurs under both physiological (e.g., tissue repair) and
pathological conditions (e.g., inflammation) [64]. The ECM consists of a complex
network of multifunctional and structural molecules, including various collagen
isoforms, adhesive glycoproteins, and proteoglycans. This network provides sup-
port to cells and to the signaling pathways that control their migration, prolifera-
tion, and differentiation. Also, the ECM might serve as a reservoir of cytokines and
other growth factors, which are released into the system in variable amounts
depending on the pathological condition.
ECM remodeling plays a central role in the differentiation of adipocytes.
Although the corresponding molecular mechanisms are only partially understood,
ECM remodeling occurs concomitantly with the activation and/or repression of a
transcriptional “network” involved in adipogenesis, which may be activated or
repressed due to extracellular stimuli [65]. In the 3 T3-L1 mouse cell line, the
differentiation of adipocytes is associated with a reduction in the fibronectin-rich
matrix and basal lamina formation [66, 67]. Silencing of the pericellular collagen
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membrane type-1 matrix metalloproteinase (Mt1-Mmp) gene in the course of the
mouse development results in the formation of a rigid collagen fibril chain and
changes in vivo adipogenesis [68]. This condition is an example of the relationship
between structural changes in ECM and adipocyte differentiation.
ECM remodeling plays a central role in the differentiation of adipocytes.
Although the similar molecular mechanisms are only partially understood, ECM
remodeling occurs concomitantly with the activation and/or repression of a tran-
scriptional “network” involved in adipogenesis, which may be activated or
repressed due to extracellular stimuli [69]. While some such alterations, such as
changes in collagen content deposition, an increase in the number of infiltrated cells
and insulin resistance, are also present in cancer-related cachexia, very little is
known regarding the possible relationship between these cell types (e.g. fibroblasts,
pre-adipocytes, immune cells, and others) and the processes that lead to ECM
remodeling.
In MAC16 tumor-bearing mice, a cancer cachexia animal model, shrunken adi-
pocytes and increased collagen-fibril content in AT were reported [18]. In CC
patients, our group recently showed that the total type I collagen content of the
scAT is rearranged in cachectic individuals with gastrointestinal cancer, which is
associated with an increase in macrophage and lymphocyte contents. Interestingly,
the total collagen content exhibited discrete changes in cancer patients without
cachexia, but the expression of the Ccl2 gene was found to be increased [20].
Another exciting finding demonstrates that ECM remodeling of AT in cancer
cachexia results in augmented collagen fiber content. Excessive synthesis of mature
elastic fibers accompanies such morphological scenery, besides strong labeling for
collagen type I (COL1) and III (COL3) in the AT from cachectic patients [30, 31].
Besides, the presence of fibrosis was also associated with an increased number of
myofibroblasts and an activated TGFβ/SMAD pathway in the subcutaneous AT of
gastrointestinal cancer cachectic patients [31, 70].
These findings indicate that the morphological changes that lead to AT
remodeling in CC patients are evident, albeit discretely, before the onset of the
earliest characteristic symptoms of cachexia (Figure 1). However, to the best of our
knowledge, no study has yet investigated the causes and repercussions of fat
remodeling in the course of cachexia in full detail.
1.2.6 Browning of adipose tissue induced by cancer cachexia
Within the set of morphofunctional changes that result in the AT remodeling, it
has recently been shown that cachexia induces browning of AT in addition to
changes in immune-modulatory activity. In this scenario, chronic inflammation and
β-adrenergic activation of thermogenesis functionally cooperate in the pathogenesis
of cachexia [16, 33, 62, 71]. In general, browning of AT has been described as
responsible for the increase in total caloric expenditure [72], and the induction of
browning has therapeutic potential in promoting the reduction of body fat [16, 33,
34, 73]. However, this fact refers to conditions of diseases characterized by the
presence of metabolic disorders, usually associated with high caloric intake, over-
weight, and/or obesity [74].
In this sense, in CC, the presence of the browning phenotype has shown to be
detected very early [16] in different experimental models [33, 34, 35]. Also, it has
demonstrated a significant role in altering the metabolism of this tissue because this
process is related to the increase in energy expenditure and mobilization of fatty
acids [17] by adipocytes. Another interesting new fact was that, in this same study,
AT from cachectic mice showed upregulation of particular genes for brown
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adipocytes when compared to samples of brown adipose tissue. This fact is not usual
because the one would expect an increase in genes specific to beige adipocytes. Also,
regarding thermogenesis, the rectal temperature was reduced when the main clini-
cal signs of the diseases were already established (refractory cachexia). Interest-
ingly, this hypothermic phenotype has previously been described in the Walker 256
tumor-induced cachexia model, in the final stage of cachexia [75]. On the other
hand, additional studies are needed to clarify the immuno-metabolic changes
resulting in thermogenic adjustments induced by the syndrome, as well as the
particular clinical consequences.
In this same study [33], the browning phenotype has also been described in
samples of visceral adipose tissue from cancer cachexia patients. However, there is a
need for analysis in a larger cohort and additional characterizations about the
possible physiological repercussions for these patients. Also, there is still a need to
characterize the real contribution of AT browning to overall energy expenditure
during cancer cachexia. In this sense, an elegant study has evaluated, in several
experimental models, that although the studies above detected mild induction of
Ucp1 mRNA levels in tumor-exposed AT, such changes appear to be discrete in
thermogenic terms [53]. In this scenario, the overall effect of AT UCP1-dependent
thermogenesis on systemic energy homeostasis may not be the principal actor
during cancer cachexia.
2. Concluding remarks
In summary, several studies have shown that AT is significantly affected during
the development of cachexia. The main alterations related to metabolic disorders,
particularly those involving early adipocyte lipid turnover dysfunction of AT,
increases in immune cell infiltration followed by increased local production of
inflammatory mediators and remodeling of ECM components. More recently, some
studies have shown that cachexia-induced browning of AT is a characteristic phe-
notype that arises from alterations that result in the AT remodeling, although its
function is still not well characterized. Nevertheless, studies using those experi-
mental models have consistently indicated that the modifications in the adipocyte
metabolism begin quite early, and the metabolites derived from this process may be
the initial (sterile) trigger of the sequence of events that result in the remodeling
and consequent dysfunction of AT in cachexia. Finally, a deeper understanding of
the initial stimulus that triggers AT dysfunction, in particular, inflammation and
remodeling, needs to be further studied because evidence indicates that AT dys-
function plays a significant role in cachexia and may be a potential modulator of the
process that could be explored therapeutically.
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Appendices and nomenclature
ECM extracellular matrix




sTNFR soluble tumor necrosis factor-α receptor
sIL-6R soluble IL-6 receptor






scAT subcutaneous adipose tissue
CD cluster of differentiation
ATMϕs adipose tissue macrophage
CD3 cluster of differentiation 3
Ly lymphocytes
HIV human immunodeficiency virus
LPL lipoprotein lipase
LLC Lewis lung carcinoma
K5-SOS-F keratinocyte-specific expression of an HA tagged dominant
form of the human SOS1
TG triacylglycerol
NEFAs non-esterified fatty acids AMPK
AMPK 50 adenosine monophosphate-activated protein
CIDEA cell death-inducing DFFA-like effector a
C/EBP CCAAT/enhancer-binding proteins
PPARγ peroxisome proliferator-activated receptor gamma
SREBP-1C sterol regulatory element-binding protein-1C
ACC acetyl-CoA carboxylase
FAS fatty acid synthase
SCD-1 stearoyl-CoA desaturase-1
GPAT glycerol-3-phosphate acetyltransferase
aP2 adipocyte fatty acid-binding protein
FATPs fatty acid transport proteins
FABPs fatty acid-binding proteins
GLUT-4 glucose transport 4
UCP mitochondrial uncoupling proteins
3 T3-L1 embryo fibroblast cells with a continuous substrain (L1) of 3T3
(Swiss albino) developed through clonal isolation
M1 polarized macrophages 1
M2 polarized macrophages 2
CCL chemokine (C-C motif) ligand
CXCL chemokine (C-X-C motif) ligand
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MT1-MMP collagen membrane type-1 matrix metalloproteinase
MAC16 murine adenocarcinoma 16
CCR2 (MCP-1) C-C chemokine receptor type 2
COL1 collagen type I
COL3 collagen type III
TGFβ transforming growth factor beta
SMAD small worm phenotype mothers against decapentaplegic
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